KEY TAKEAWAYS
- The study aimed to evaluate the effectiveness of combined targeted therapy, immunotherapy, and HAIC of FOLFOX in patients with unresectable HCC.
- Researchers concluded that the combined regimen effectively treated patients with unresectable HCC.
The advent of cutting-edge systemic therapies has driven advances in the treatment of hepatocellular carcinoma (HCC), and therapeutic strategies with multiple modes of delivery have been shown to be more efficacious than monotherapy. However, the mechanisms underlying this innovative treatment modality have not been elucidated.
Zhi-Peng Lin and the team aimed to investigate the effectiveness of combining targeted therapy and immunotherapy with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX in treating unresectable HCC.
They performed an inclusive analysis on 53 patients diagnosed with unresectable HCC who underwent combination therapy, including targeted therapy, immunotherapy, and HAIC of FOLFOX, between December 2020 and June 2021. The efficacy and safety of this treatment regimen were thoroughly evaluated.
The objective response rate was 60.4% (32/53), with complete response at 24.5% (13/53), and partial response at 35.9% (19/53). Additionally, stable disease was observed in 39.6% (21/53) of cases. The median duration of response was 9.1 months, while median progression-free survival was 13.9 months. A surgical conversion rate of 34.0% (18/53) was noted. The 1-year overall survival rate reached 83.0%, with no critical complicating diseases or adverse events (AEs).
The study concluded that the regimen comprising HAIC of FOLFOX, targeted therapy, and immunotherapy demonstrated remarkable efficacy in treating patients with unresectable HCC. Notably, this treatment approach was associated with a high rate of surgical conversion and an absence of serious AEs, indicating its potential as a curative option for this patient population.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/38813052/
Lin ZP, Hu XL, Chen D, et al. (2024). “Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.” World J Gastroenterol. 2024 May 7;30(17):2321-2331. doi: 10.3748/wjg.v30.i17.2321. PMID: 38813052; PMCID: PMC11130568.
